Heptares granted patents covering stabilised receptor technology in Europe and Japan
Key patent grants protect Heptares’ leading position in GPCR-targeted drug design and discovery
This patent family broadly covers methods for transforming GPCRs, which are highly unstable when removed from cellular membranes, into stabilised forms (StaRs®) corresponding to selected pharmacologically relevant conformations using any method of mutagenesis, expression or assay. The unique properties of StaRs® have enabled Heptares to build a powerful and integrated platform designed to exploit, for the first time, the full range of structure-based approaches for drug discovery. Using this approach, the Company is building a pipeline of first-in-class and best-in-class GPCR-targeted medicines, with a focus on CNS and metabolic indications.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.